Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC)

Shanghai 10th People's Hospital300 enrolled

Overview

Integrative Analysis of pulmonary sarcomatoid carcinoma (PSC)

The investigators will analyzed proteomes of paired normal lung tissues and pulmonary sarcomatoid carcinoma with or without metastasis, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal lung tissue, primary pulmonary sarcomatoid carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of lung cancer characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Lung Cancer

Interventions

The investigators will extract total protein, DNA and RNA from PSC patients.OTHER

The investigators will extract total protein, DNA and RNA from PSC patients.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≤ 70 years with histologically proven LCLC * No severe major organ dysfunction * World Health Organization (WHO) performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 70 * Severe major organ dysfunction * WHO performance status of \>1 * Prior cancer chemotherapy

Locations (1)

Da Fu

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

10 years overall survival

Time frame: 10 years overall survival

Secondary Outcomes

10 years disease-free survival

Time frame: 10 years disease-free survival

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.